目的 探究珠贝定喘丸联合丙酸倍氯米松气雾剂治疗支气管哮喘的临床疗效。方法 选择2016年4月—2018年12月在天津市蓟州区人民医院就诊的138例支气管哮喘患者作为研究对象，将所有患者随机分为对照组和治疗组，每组各69例。对照组吸入丙酸倍氯米松气雾剂，50 μg/次，15～20 min内吸入完毕，3次/d。治疗组在对照组治疗的基础上含服或用温开水送服珠贝定喘丸，6粒/次，3次/d。两组患者均连续治疗15 d。观察两组的临床疗效，比较两组的临床症状消失时间、肺功能指标、炎症因子水平。结果 治疗后，对照组和治疗组的总有效率分别为81.16%、97.10%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患者的咳嗽消失时间、喘息消失时间、肺部哮鸣音消失时间、咳痰消失时间均显著短于对照组，两组差异有统计学意义（P<0.05）。治疗后，两组患者第一秒用力呼气容积（FEV1）、最大呼气流量（PEF）、肺活量（VC）均显著增加，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组患者肺功能指标明显高于对照组，两组差异有统计学意义（P<0.05）。治疗后，两组患者白细胞介素-4（IL-4）、肿瘤坏死因子-α（TNF-α）水平均显著降低，γ-干扰素（IFN-γ）水平显著升高，同组治疗前后比较差异有统计学意义；且治疗后治疗组患者炎症因子水平显著优于对照组，两组差异有统计学意义（P<0.05）。结论 珠贝定喘丸联合丙酸倍氯米松气雾剂治疗支气管哮喘具有较好的疗效，可显著缓解临床症状，提高患者肺功能，改善血清炎性因子水平，且安全性较高，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Zhubei Dingchuan Pills combined with Beclometasone Dipropionate Aerosol in treatment of bronchial asthma. Methods Patients (138 cases) with bronchial asthma in the People's Hospital of Jizhou District of Tianjin from April 2016 to December 2018 were randomly divided into control and treatment groups, and each group had 69 cases. Patients in the control group were inhalation administered with Beclometasone Dipropionate Aerosol, 50 μg/time, and completed inhalation within 15 - 20 min, three times daily. Patients in the treatment group were po administered with Zhubei Dingchuan Pills on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacies were evaluated, and the disappearance time of clinical symptoms, and lung function indexes and inflammatory factor levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.16% and 97.10%, respectively, and there was difference between two groups (P<0.05). After treatment, Cough disappearance time, wheezing disappearance time, lung wheezing disappearance time, and sputum disappearance time in the treatment group were shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment, FEV1, PEF and VC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of IL-4 and TNF-α in two groups were significantly decreased, but the levels of IFN-γ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory factor levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Zhubei Dingchuan Pills combined with Beclometasone Dipropionate Aerosol has clinical curative effect in treatment of bronchial asthma, can significantly alleviate clinical symptoms, increase lung function, and improve serum inflammatory factors levels, with good safety, which has a certain clinical application value.